Applying latent profile analysis to identify adolescents and young adults with chronic conditions at risk for poor health-related quality of life.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Suwei Wang, Cara J Arizmendi, Dandan Chen, Li Lin, Dan V Blalock, I-Chan Huang, David Thissen, Darren A DeWalt, Wei Pan, Bryce B Reeve
{"title":"Applying latent profile analysis to identify adolescents and young adults with chronic conditions at risk for poor health-related quality of life.","authors":"Suwei Wang, Cara J Arizmendi, Dandan Chen, Li Lin, Dan V Blalock, I-Chan Huang, David Thissen, Darren A DeWalt, Wei Pan, Bryce B Reeve","doi":"10.1080/10543406.2023.2210684","DOIUrl":null,"url":null,"abstract":"<p><p>The impact of chronic diseases on health-related quality of life (HRQOL) in adolescents and young adults (AYAs) is understudied. Latent profile analysis (LPA) can identify profiles of AYAs based on their HRQOL scores reflecting physical, mental, and social well-being. This paper will (1) demonstrate how to use LPA to identify profiles of AYAs based on their scores on multiple HRQOL indicators; (2) explore associations of demographic and clinical factors with LPA-identified HRQOL profiles of AYAs; and (3) provide guidance on the selection of adult or pediatric versions of Patient-Reported Outcomes Measurement Information System® (PROMIS®) in AYAs. A total of 872 AYAs with chronic conditions completed the adult and pediatric versions of PROMIS measures of anger, anxiety, depression, fatigue, pain interference, social health, and physical function. The optimal number of LPA profiles was determined by model fit statistics and clinical interpretability. Multinomial regression models examined clinical and demographic factors associated with profile membership. As a result of the LPA, AYAs were categorized into 3 profiles: Minimal, Moderate, and Severe HRQOL Impact profiles. Comparing LPA results using either the pediatric or adult PROMIS T-scores found approximately 71% of patients were placed in the same HRQOL profiles. AYAs who were female, had hypertension, mental health conditions, chronic pain, and those on medication were more likely to be placed in the Severe HRQOL Impact Profile. Our findings may facilitate clinicians to screen AYAs who may have low HRQOL due to diseases or treatments with the identified risk factors without implementing the HRQOL assessment.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"888-901"},"PeriodicalIF":1.2000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2023.2210684","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The impact of chronic diseases on health-related quality of life (HRQOL) in adolescents and young adults (AYAs) is understudied. Latent profile analysis (LPA) can identify profiles of AYAs based on their HRQOL scores reflecting physical, mental, and social well-being. This paper will (1) demonstrate how to use LPA to identify profiles of AYAs based on their scores on multiple HRQOL indicators; (2) explore associations of demographic and clinical factors with LPA-identified HRQOL profiles of AYAs; and (3) provide guidance on the selection of adult or pediatric versions of Patient-Reported Outcomes Measurement Information System® (PROMIS®) in AYAs. A total of 872 AYAs with chronic conditions completed the adult and pediatric versions of PROMIS measures of anger, anxiety, depression, fatigue, pain interference, social health, and physical function. The optimal number of LPA profiles was determined by model fit statistics and clinical interpretability. Multinomial regression models examined clinical and demographic factors associated with profile membership. As a result of the LPA, AYAs were categorized into 3 profiles: Minimal, Moderate, and Severe HRQOL Impact profiles. Comparing LPA results using either the pediatric or adult PROMIS T-scores found approximately 71% of patients were placed in the same HRQOL profiles. AYAs who were female, had hypertension, mental health conditions, chronic pain, and those on medication were more likely to be placed in the Severe HRQOL Impact Profile. Our findings may facilitate clinicians to screen AYAs who may have low HRQOL due to diseases or treatments with the identified risk factors without implementing the HRQOL assessment.

应用潜在特征分析来识别患有慢性疾病的青少年和年轻成年人与健康相关的生活质量较差的风险。
慢性疾病对青少年健康相关生活质量(HRQOL)的影响研究不足。潜在特征分析(LPA)可以根据青少年的 HRQOL 分数(反映身体、精神和社会福祉)识别他们的特征。本文将(1)展示如何使用 LPA 根据亚健康人群在多个 HRQOL 指标上的得分来识别亚健康人群的特征;(2)探讨人口统计学和临床因素与 LPA 识别的亚健康人群 HRQOL 特征之间的关联;(3)为亚健康人群选择成人版或儿科版的患者报告结果测量信息系统 (Patient-Reported Outcomes Measurement Information System®, PROMIS®) 提供指导。共有 872 名患有慢性疾病的亚健康患者完成了成人版和儿科版 PROMIS 对愤怒、焦虑、抑郁、疲劳、疼痛干扰、社交健康和身体功能的测量。LPA 配置文件的最佳数量由模型拟合统计和临床可解释性决定。多项式回归模型检查了与个人档案成员资格相关的临床和人口学因素。根据 LPA 的结果,AYAs 被分为 3 个特征:轻度、中度和重度 HRQOL 影响特征。使用儿童或成人 PROMIS T 分数比较 LPA 结果发现,约 71% 的患者被归入相同的 HRQOL 档案。女性、患有高血压、精神疾病、慢性疼痛和正在服药的亚健康患者更有可能被归入严重 HRQOL 影响档案。我们的研究结果可帮助临床医生在不进行 HRQOL 评估的情况下,筛选出那些因疾病或治疗而导致 HRQOL 低下的亚健康人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信